Legal explainer · from the 250-topic plan
Telehealth prescribing law 101: the legal stack under every legitimate GLP-1 program
Five layers of law stand under every legitimate compounded-GLP-1 sale: state medical licensure (the clinician must hold a license where you are), a valid patient-clinician relationship formed to your state's telehealth standard, informed consent that names the compounded, non-FDA-approved status, the corporate-practice-of-medicine architecture that keeps business entities out of clinical judgment, and 503A pharmacy law — patient-specific prescriptions with, post-shortage, a documented clinical rationale, dispensed by a pharmacy licensed in your state. One frequent myth dies early: GLP-1s aren't controlled substances, so the Ryan Haight in-person rules people cite don't apply. Every layer maps to a question you can ask; that's the point of learning the stack.
Layer 1: the license follows the patient
Medicine is state-regulated, and the rule of the road is that the prescriber must be licensed in the state where the patient is located during the encounter — which is why real programs verify your state before anything else, why served-states lists exist, and why a program with no state-gating is advertising its indifference to layer one. Interstate licensure compacts speed multi-state credentialing for physicians; they don't repeal the requirement.
Layer 2: what makes the relationship valid
A prescription legally requires an established patient-clinician relationship, and states define the telehealth version: most now accept a proper asynchronous or synchronous evaluation — a structured history a licensed clinician actually reviews, with the ability to ask follow-ups and, critically, to decline — while a minority demand synchronous elements for some care. The universal floor everywhere: a questionnaire nobody reads is not an evaluation, and “the quiz that can't say no” (field-manual flag 2) fails this layer regardless of state.
Layer 3: consent that names the thing
Informed consent for compounded therapy has a specific job: the patient must be told, before agreeing, that the product is compounded and not FDA-approved, what the material risks and alternatives are (including the approved brands), and — for telehealth — the modality's own limits. A program whose consent flow buries or omits the compounded status hasn't cut a corner; it's cut the layer, and several state actions in this industry have turned on exactly that omission.
Layer 4: who is allowed to own the medicine
Most states prohibit lay corporations from practicing medicine or employing physicians to do so — the corporate-practice-of-medicine doctrine — which is why legitimate telehealth runs the familiar architecture: a physician-owned professional entity making all clinical decisions, contracting with a management company (the brand you see) for everything non-clinical. The doctrine's consumer meaning is blunt: clinical judgment may not report to the marketing department. The observable tells: nameable medical leadership, prescribers who decline, titration governed by clinicians rather than refill autopilot — the same tells the field manual's flags 2 and 3 already screen.
Layer 5: the pharmacy's own stack
503A law makes compounding legal only as patient-specific practice — a named patient, a valid prescription, and, since the shortage designations ended, a documented clinical rationale for using a compounded version instead of the available approved product. Layer onto that the licensure chain (home-state plus nonresident licensure in yours — the walkthrough) and the FDA's salt-form and labeling rules, and the pharmacy half of the stack becomes fully checkable from public records. Mass-produced “compounding” without individual prescriptions isn't a gray area; it's the thing the 2025–26 enforcement letters are about.
The Ryan Haight myth, retired
Skeptical relatives cite “the law requiring an in-person visit.” That's the Ryan Haight Act — and it governs controlled substances, which GLP-1s are not. Telehealth GLP-1 prescribing is governed by the five state-law layers above, not by DEA in-person rules. The distinction matters in both directions: it's why legitimate fully-remote programs exist at all, and why “we're online so the rules are lighter” is backwards — the rules are the same five layers, just easier to skip quietly. Which returns to this site's whole method: every layer maps to a question — Which clinician, licensed where? What did the evaluation actually review? Where does your consent name the compounded status? Who owns the clinical entity? Which pharmacy, licensed in my state, on what rationale? — and the programs that answer all five in writing are the only ones this database ranks. A file that answers in writing ↗
FAQ
Is it legal to get GLP-1s prescribed online?
Yes, when the stack is honored: a clinician licensed in your state, a valid telehealth evaluation, informed consent naming the compounded status, proper clinical-entity structure, and a 503A pharmacy licensed for your state dispensing on a patient-specific prescription with documented rationale.
Does the law require an in-person visit for GLP-1s?
No — the Ryan Haight in-person rules govern controlled substances, which GLP-1s are not; state telehealth-evaluation standards govern instead.
What is the corporate practice of medicine doctrine?
State rules barring lay companies from making or employing clinical judgment — the reason legitimate telehealth separates a physician-owned clinical entity from the consumer brand, and why prescribers must be able to say no.
What makes a compounded GLP-1 prescription valid post-shortage?
Patient-specific prescribing with a documented clinical rationale for the compounded version, dispensed by a properly licensed 503A — mass production without individual prescriptions is what current enforcement targets.
Sources
- State medical-board telehealth standards and licensure rules; interstate compact frameworks.
- Corporate-practice-of-medicine doctrines and MSO structures.
- FD&C Act §503A; FDA post-shortage compounding policy and 2025–26 enforcement letters.
- Ryan Haight Act scope (controlled substances) — inapplicability to GLP-1s.